ARTICLE | Discovery & Translation
Across disciplines, researchers are navigating trade-offs in advancing translation that boil down to scope versus focus
By Karen Tkach Tuzman, Director of Biopharma Intelligence
September 27, 2024 11:43 PM UTC
When it comes to maximizing the therapeutic impact of early-stage R&D, you can’t have it all — at least not without new paradigms.
Companies and academics must either pick which parameters are most important to them, or innovate new paths that thread the needle between often opposed factors. At heart, it boils down to a question of scope versus focus. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653660/three-tensions-in-early-stage-translation-biocentury-grand-rounds